From intensifying therapy in ctDNA-positive bladder cancer to scaling it back in ctDNA-negative colon cancer, new data from ...

Median disease-free survival (DFS) increased from 4.8 months with placebo to 9.9 months with adjuvant atezolizumab (Tecentriq ...

Patients with muscle-invasive bladder cancer have varied outcomes after cystectomy. Circulating tumor DNA (ctDNA)–based ...

Data at ESMO 2025 bolstered the case that blood tests could help doctors sort which patients need additional therapy, and who ...

To kick things off, we'll set the stage on what defines non-muscle invasive bladder cancer and how we triage patient ...

(Reuters) -Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor ...

The combination of Merck’s Keytruda and Pfizer and Astellas’ Padcev reduced patients' risk of death by a whopping 50% when used before and after bladder removal surgery in those with MIBC who are not ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the ...

FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma ...

A newer class of cancer drugs can delay disease progression or extend survival for breast cancer patients, multiple teams of ...

DENVER (KDVR) — The University of Colorado Buffaloes head coach Deion Sanders said on Monday that he was absent from coaching because he had his bladder removed after doctors found a tumor. Sanders ...